Anvisa bans irregular insulin and peptide sales in Brazil

Brazil’s National Health Surveillance Agency (Anvisa) has prohibited the sale and use of all insulin glargine (3 mL/100 UI) batches distributed by Costa Mar Comércio Licitatório. An inspection in Petrópolis revealed the company lacked the necessary operating authorization and was not functioning at its registered address.

Additionally, Anvisa ordered the seizure of several unregistered peptides sold online, including tirzepatide, retatrutide, BPC157, TB500, NAD+, and GHK-CU. These products, marketed through sites such as Peptídeos Pro, are prohibited from being manufactured, distributed, or used due to a lack of sanitary registration.

The agency also addressed other medical recalls: Janssen-Cilag Farmacêutica initiated a voluntary recall of Imaavy 300 mg (lot JNYJ1201) due to potential glass particles in the vials, and Halex Istar Indústria Farmacêutica recalled Lizbi 2 mg/ml (lot 0000207107) following a loss of sterility caused by packaging issues.